

P. Steinberg · A. Klingelhöffer · A. Schäfer
G. Wüst · G. Weiße · F. Oesch · E. Eigenbrodt

Expression of pyruvate kinase M₂ in preneoplastic hepatic foci of *N*-nitrosomorpholine-treated rats

Received: 24 March 1998 / Accepted: 13 November 1998

Abstract The expression of the pyruvate kinase (PK) isoenzymes L and M₂ was analysed in the livers of rats treated with the hepatocarcinogenic agent *N*-nitrosomorpholine (NNM) in the drinking water. In control animals L-PK expression was restricted to liver parenchymal cells, whereas M₂-PK was detected in bile duct epithelial, blood vessel wall, endothelial and Kupffer cells. In rats treated with NNM proliferating oval cells were consistently L-PK negative and M₂-PK positive, while the ductal cells of cholangiofibroses were clearly L-PK positive and coexpressed M₂-PK. However, no morphological differentiation of ductal cells into hepatocyte-like cells was observed. In the clear and acidophilic cell foci storing glycogen in excess strong staining for L-PK was observed. In glycogen-poor foci induced by NNM a shift from L-PK to M₂-PK expression takes place.

Key words Pyruvate kinase isoenzymes · *N*-Nitrosomorpholine · Rat

Introduction

The sequential cellular changes occurring during the development of hepatocellular and cholangiocellular carcinomas induced in the rodent liver by a variety of chemical carcinogens have been analysed extensively. The pre-

dominant cell lineage observed during the development of hepatocellular carcinomas in the rat ranges from clear and acidophilic cell foci, which store glycogen in excess and may be acidophilic due to the proliferation of smooth endoplasmic reticulum, through mixed and basophilic (ribosome-rich) cell foci to hepatocellular adenomas and carcinomas [3]. The development of cholangiocellular neoplasms proceeds in four stages: proliferation of oval cells in response to the toxic effects of the chemicals on the liver parenchymal cells; appearance of cholangiofibroses, in which the bile duct epithelial cells store and secrete neutral and acidic mucopolysaccharides; appearance of cholangiofibromas, which grow expansively and produce collagen fibres and also mucous substances; appearance of cholangiocarcinomas, which grow invasively and show a gradual decrease of mucus production [4, 5, 19, 30]. Oval cells are liver epithelial cells that proliferate during the early stages of hepatocarcinogenesis and severe liver injury induced by many chemicals [1]. It has been suggested that oval cells can not only give rise to cholangiocellular carcinomas, as mentioned above, but can also differentiate into basophilic parenchymal cells under particular experimental conditions and lead to the formation of hepatocellular carcinomas [11, 12, 14, 23, 24, 27, 28]. These authors postulate that oval cells should be viewed as bipotent tumour precursor cells that can give rise to hepatocellular as well as cholangiocellular carcinomas.

Pyruvate kinase (PK) is one of the key enzymes of carbohydrate metabolism, controlling the glucose flow throughout the later part of glycolysis [9]. There are several PK isoenzymes: the L-type is present in liver parenchymal cells and proximal kidney tubules, while the M₂-type is detected in liver mesenchymal and bile duct epithelial cells and also in distal kidney tubules.

Findings published on the expression of L- and M₂-PK during hepatocarcinogenesis are controversial. Early biochemical studies showed that the expression of L-PK was down-regulated and that of M₂-PK up-regulated within transplantable and primary hepatocellular tumours [8, 13, 26, 29, 32, 37–39]. Whereas a number of

P. Steinberg · A. Klingelhöffer · F. Oesch
Institute of Toxicology, University of Mainz,
Mainz, Germany

P. Steinberg (✉)
Institut für Ernährungswissenschaft, Universität Potsdam,
Arthur Scheunert-Allee 114–116, D-14558 Bergholz-Rehbrücke,
Germany
Fax: +49-33200-88573

A. Schäfer · G. Wüst · G. Weiße
Institute of Toxicology, E. Merck KGaA,
Darmstadt, Germany

E. Eigenbrodt
Institute of Biochemistry and Endocrinology,
University of Giessen, Darmstadt, Germany

later biochemical and immunohistochemical studies confirmed the decrease in the expression of L-PK during the development of hepatocellular tumours [15–18, 21, 22, 25], this shift from L- to M₂-PK could not be reproduced when the phenomenon was investigated by immunohistochemistry [25]. Furthermore, Klimek and Bannasch [21] reported that PK activity was actually increased in the clear and acidophilic cell foci that appeared early in the process and that it decreased both in mixed and basophilic cell foci and in basophilic hepatic tumours, (during the later stages of hepatocarcinogenesis). Very recently Hacker et al. [20] have been able to show for the first time, in serial liver sections from rats fed a choline-deficient/DL-ethionine CDE-supplemented diet, that a shift from L- to M₂-PK expression takes place in mixed cell foci and hepatocellular adenomas.

In cholangiocarcinogenesis, it has been shown that M₂-PK is present in proliferating oval cells as well as in the ductal cells of cholangiofibroses and cholangiofibromas of CDE-fed rats [31, 33–36]. Interestingly, in this experimental model the proliferating oval cells and the ductal cells of cholangiofibroses and cholangiofibromas also express L-PK [31, 33–36]. The interpretation of this observation has varied. According to Yeoh et al. [35, 36], the presence of L-PK, a specific parenchymal cell marker in untreated rat liver, in oval cells strongly suggests that oval cells are able to differentiate into liver parenchymal cells. However, Steinberg et al. [31] have clearly shown that, according to morphology, the ductal cells expressing L-PK within cholangiofibroses and cholangiofibromas are part of the bile duct epithelial cell lineage.

To test whether the shift from L-PK to M₂-PK expression in hepatocellular lesions reported by Hacker et al. [20] was exclusively due to CDE feeding or whether it represented a biochemical phenomenon observed in other models of chemically induced hepatocarcinogenesis, we analysed the expression of L-PK and M₂-PK in the cholangiocellular and hepatocellular lesions of rats that had been exposed to *N*-nitrosomorpholine (NNM) for up to 3 weeks. NNM was chosen because it has been used in the past to induce hepatocellular neoplasms in rats [4, 5, 7, 10]. In the present study we show that: M₂-PK and L-PK are coexpressed in ductal cells within cholangiofibroses of NNM-treated rats and that in glycogen-poor basophilic cell foci appearing in the livers of NNM-treated animals a shift from L-PK to M₂-PK expression takes place.

Materials and methods

Forty-eight male outbred 6-week-old Wistar rats from Charles River (Sulzfeld, Germany) were housed in plastic cages on a fixed day and night cycle and exposed to 500 mg NNM/l drinking water for 5, 10, 14 or 21 days. Animals were either sacrificed at these time-points or kept for another 4 weeks without being further exposed to NNM. Forty-eight rats not given NNM were used as controls and were sacrificed in groups of six at the given time-points. Livers were quickly removed under light ether anaesthesia, and liver slices ~2 mm thick were prepared. Slices of liver were fixed in 10% formalin in phosphate-buffered saline, and sections of for-

malin-fixed liver samples were stained with haematoxylin and eosin for the light microscopic examination of liver structure. Other slices of liver were fixed in acetone for 4 days at 4°C (acetone being changed three times during the 4-day period), and then laid in isopropanol for 4–8 h and in xylol for another 2 h. Thereafter, paraffin blocks were prepared and sections of these liver samples were incubated with monoclonal antibodies against L-PK (clone AD12) and M₂-PK (clone DF4) (ScheBoTech, Wettenberg, Germany). The site of antibody binding was revealed by using the peroxidase–antiperoxidase method as previously described [15], and the liver slices were counterstained with Mayer's haematoxylin.

Results

The histopathological features of the livers from rats exposed to NNM were described in detail by Bannasch's group a number of years ago [4, 5]. Since our own light microscopic observations in no way differed from those recorded by Bannasch's group [4, 5], only a brief description of the hepatic lesions observed in the course of this study is presented here. Five days after the beginning of the NNM treatment, necrosis of a significant number of liver parenchymal cells situated centrilobularly was observed and the area was largely replaced by red blood cells. Up to day 21 liver parenchymal cell necrosis became increasingly pronounced, and within the necrotic areas liver parenchymal cells with an eosinophilic cytoplasm and polymorphic nuclei were observed. Mild oval cell proliferation was observed in the periportal areas of the lobules as soon as 5 days after the start of the NNM treatment. By day 21 a marked oval cell proliferation had developed, and areas of cholangiofibrosis containing ducts formed (in part) by tall columnar cells were observed.

In rats that had received NNM for 5 or 10 days and were sacrificed 4 weeks later, no necrotic areas were visible and most of the oval cells had disappeared. Furthermore, up to three clear and acidophilic cell foci/liver lobe were observed. In animals that had been treated with NNM for 14 or 21 days and had then been kept without NNM for another 4 weeks, the normal architecture of the liver was completely distorted and pseudolobules had formed. The pseudolobules were surrounded by fibrotic septa including many oval cells and contained mainly clear and acidophilic cell populations: these cells were confined to focal lesions (up to 10 foci/liver lobe) or occupied large areas of the pseudolobules. In addition, in those animals that had received NNM for 21 days and

Fig. 1 **a** Expression of L-PK in the liver of an untreated rat: only parenchymal cells are stained. $\times 100$. **b** Expression of M₂-PK in the liver of an untreated rat: only bile duct epithelial, blood vessel wall and sinusoidal lining cells are stained. $\times 400$

Fig. 2 L-PK distribution in the liver of a rat treated 10 days with *N*-nitrosomorpholine (NNM): L-PK is not detected in the centrilobular necrotic areas, while its expression is strongly reduced in the remaining hepatocytes. $\times 100$

Fig. 3 M₂-PK expression is restricted to oval and ductal cells in the liver of a rat treated for 14 days with NNM. $\times 400$







Fig. 4 **a** L-PK and **b** M₂-PK are present in the ductal cells of a cholangiofibrosis that developed within the liver of a rat treated for 21 days with NNM. Serial sections, $\times 400$

Fig. 5 M₂-PK-positive focus adjacent to M₂-PK-positive oval and ductal cells in a rat treated for 21 days with NNM. $\times 400$









Fig. 6 L-PK-positive and -negative foci in the liver of a rat treated for 21 days with NNM and sacrificed 4 weeks later. $\times 100$

Fig. 7 a L-PK and **b** M₂-PK expression in a liver focus of a rat treated for 21 days with NNM and sacrificed 4 weeks later. $\times 100$



were sacrificed 4 weeks later up to three mixed and basophilic cell foci/liver lobe as well as cholangiofibroses were observed.

The specificity of the monoclonal antibodies against L-PK and M₂-PK was tested on liver slices from untreated rats. L-PK expression was restricted to liver parenchymal cells (Fig. 1a), whereas M₂-PK was detected in bile duct epithelial, blood vessel wall, endothelial and Kupffer cells (Fig. 1b). In rats sacrificed immediately after NNM treatment no L-PK was present within the centrilobular necrotic areas and its expression was markedly reduced in the remaining hepatocytes (Fig. 2) compared with the control tissue (Fig. 1a). While proliferating oval cells were consistently L-PK negative and M₂-PK positive (Fig. 3), staining of serial sections revealed that the ductal cells of the cholangiofibroses were clearly L-PK positive (Fig. 4a) and coexpressed M₂-PK (Fig. 4b). In addition, in animals receiving NNM for 21 days isolated M₂-PK-positive foci surrounded by M₂-PK-positive oval cells were observed (Fig. 5).

In rats that had received NNM for 5, 10, 14 or 21 days and were kept without NNM for another 4 weeks, L-PK expression in the liver parenchyma was similar to that in control animals, except for the hepatocytes arranged in foci, as described below. The number of L-PK- or M₂-PK-positive foci appearing in these animals was highly dependent on the duration of the NNM treatment. In rats receiving NNM for 5 or 10 days and sacrificed 4 weeks later 3–10 glycogen-rich, L-PK-positive foci per liver lobe were observed. In animals that had been treated with NNM for 14 or 21 days and were then maintained without NNM for 4 weeks, 10–20 L-PK-positive foci per liver lobe were seen (Fig. 6). However, up to 3, 10 and 20 glycogen-poor, M₂-PK-positive foci per liver lobe were observed in rats that had received NNM for 10, 14 or 21 days, respectively, and were sacrificed 4 weeks later. The staining of serial liver sections from these animals showed consistently that L-PK was no longer present in the M₂-PK-positive foci (Fig. 7a, b). In the four groups of animals M₂-PK again proved to be an excellent marker for all cholangiocellular lesions and L-PK was again detected in the ductal cells forming part of the cholangiofibroses but not in the proliferating oval cells (data not shown).

Discussion

In an attempt to improve our understanding of the role of different cell lineages (liver parenchymal and oval cells) in the development of experimentally induced cholangiocellular and hepatocellular carcinomas, we chose to analyse the expression of L- and M₂-PK in the livers of rats treated with a high dose of NNM for up to 3 weeks. First, the PK isoenzymes were known to be expressed in a cell type-specific way in the untreated liver (L-PK is present in liver parenchymal cells, whereas M₂-PK is restricted to bile duct epithelial, sinusoidal lining and blood vessel wall cells). Second, it had been reported

that L-PK was detectable in oval and ductal cells within the livers of rats fed CDE, while M₂-PK was regarded as a bile duct epithelial cell lineage-specific marker in the same experimental model [31, 33–35]. Third, in the past Bannasch's group had provided extensive documentation confirming that the appearance of oval cells, cholangiofibroses, clear and acidophilic cell foci, and mixed and basophilic cell foci could be induced very efficiently in rats by adding NNM to the drinking water [4, 5, 7, 10]. The decision to include animals treated with NNM for a defined time period and then maintained without NNM for 4 weeks in this study is based on the fact that in a number of experimental models foci of phenotypically altered hepatocytes were shown to disappear ("revert") after the discontinuation of carcinogen administration [2]. Therefore, Bannasch et al. [6] proposed that stop experiments should be conducted whenever foci with a disputed significance develop after the administration of a compound.

The number of oval cells remaining in the livers of rats fed NNM for 5 or 10 days and then left NNM-free for 4 weeks was far lower than the number in the livers of rats sacrificed immediately after the 5- or 10-day NNM treatment. In contrast, in animals that were treated for 14 or 21 days with NNM and then left NNM free for 4 weeks oval cell proliferation did not regress. Hacker et al. [19] showed earlier that in rats fed CDE for 4 or 6 weeks and then maintained on a standard lab chow for up to 62 weeks only a low number of oval cells were visible, whereas in rats sacrificed immediately after the 4- or 6-week CDE feeding period oval cell proliferation had been shown to be massive [30]. If the rats were fed the carcinogenic diet for 10, 14 or 22 weeks and then left on a standard lab chow for 1 year a pronounced oval cell proliferation was still observed [17]. The data obtained in the two experimental models [19, 30] (this study) suggest that many of the oval cells proliferating in the early stages of the carcinogenic process undergo necrosis and disappear with time, whereas those oval cells that have been in contact with a carcinogen for a longer period might have developed a sort of survival mechanism and remain as they were in the liver tissue or give rise to further lesions such as cholangiofibroses, cystic cholangiomas and cholangiofibromas [19, 30] (this study). In contrast to the early proliferating oval cells, the cholangiofibroses developing in the livers of NNM-treated animals in no way reverted, and these are therefore viewed as persistent cholangiocellular lesions.

As in the oval cells proliferating within the livers of CDE-fed rats [31, 33–36], M₂-PK proved to be an excellent marker for the oval cells and the ductal cells in NNM-treated animals. Interestingly, the duct cells not only expressed M₂-PK, but also stained positive for L-PK. This observation, which also applies to the ductal cells in the CDE model [31, 33–36], has been interpreted by Yeoh's group [35, 36] as strong support for the hypothesis that oval cells are able to differentiate into hepatocytes. However, in our investigations the ductal cells that stained positive for L-PK in the CDE [31] and the

NNM model [this study] showed no morphological signs of differentiation towards hepatocyte-like cells. Thus, the expression of the hepatocyte marker L-PK in a cell of the bile duct epithelial cell lineage does not allow the conclusion that such a differentiation has taken place.

The most striking result in this study is the unequivocal demonstration that during the NNM-driven hepatocarcinogenic process in rats a shift from L-PK to M₂-PK expression occurred within glycogen-poor foci. This is in accordance with a very recent paper published by Hacker et al. [20], who reported the same shift in a low number of mixed and basophilic cell foci as well as in hepatocellular adenomas developing in CDE-fed rats. In contrast to the report by Hacker et al. [20] and this study, Reinacher et al. [25] were unable to show that a decrease in L-PK in preneoplastic foci induced in rats by a single dose of NNM followed by the administration of phenobarbital or α -hexachlorocyclohexane in the diet was accompanied by the expression of M₂-PK in these foci. This discrepancy is most probably due to the fixation procedure used by Reinacher et al. [25]. As shown in this study and in that by Hacker et al. [20], acetone alone is not sufficient to fix M₂-PK within the preneoplastic lesions. In both cases a further step involving isopropanol (this study) or ethanol [20] as fixative was needed to obtain positive staining for M₂-PK in the liver slices.

Because of the expression of the oval cell marker M₂-PK in preneoplastic hepatocytes, it is tempting to suggest that the precursor cells of these M₂-PK-positive hepatocytes are the oval cells. However, it should be taken into account that most of the M₂-PK-positive foci were not surrounded by oval cells and that no oval cells were seen within these foci. Therefore, in this case we conclude that the shift of L-PK to M₂-PK occurs within the same cell type (the hepatocyte). The situation is different in the case of the few M₂-PK-positive foci that were surrounded by M₂-PK-positive oval cells (such as that depicted in Fig. 5); in this particular case it is not possible to discern whether the cell of origin of the M₂-PK-positive foci was a pre-existing hepatocyte or an oval cell.

By using a laser micro-dissection device and performing a microbiological analysis, Klimek and Bannasch [21] had previously found that in NNM-treated animals PK activity was enhanced in clear and acidophilic cell foci, and on the basis of kinetic data they concluded that the increase in PK activity was due to L-PK. Furthermore, they reported that in the same model mixed and basophilic cell foci L-PK activity decreased. The results presented in this immunohistochemical study clearly confirm the earlier work by Klimek and Bannasch [21]; the foci storing glycogen in excess overexpressed L-PK, whereas those that were poor in glycogen were L-PK negative and M₂-PK positive.

In conclusion, during the NNM-induced hepatocarcinogenic process a shift in the expression of L-PK to M₂-PK occurs in glycogen-poor foci and the ductal cells within the cholangiocellular lesions coexpress the two PK isoenzymes. In neither case is there evidence for morphological differentiation of oval cells into hepatocytes.

Acknowledgements A. Klingelhöffer was the recipient of a graduate student scholarship from E. Merck KGaA. P. Steinberg is the recipient of a Heisenberg scholarship from the Deutsche Forschungsgemeinschaft, and this study was supported by the Heisenberg-Programme with grant Ste 493/2-1.

References

1. Aterman K (1992) The stem cells of the liver – a selective review. *J Cancer Res Clin Oncol* 118:87–115
2. Bannasch P (1986) Preneoplastic lesions as end points in carcinogenicity testing. I. Hepatic preneoplasia. *Carcinogenesis* 7:689–695
3. Bannasch P (1996) Pathogenesis of hepatocellular carcinoma: sequential cellular, molecular and metabolic changes. In: Boyer JL, Ochner RK (eds) *Progress in liver diseases*, vol. XIV. Saunders, Orlando, pp 161–197
4. Bannasch P, Massner B (1976) Histogenese und Cyto-genese von Cholangiofibromen und Cholangiocarcinomen bei Nitrosomorpholin-vergifteten Ratten. *Z Krebsforsch* 87:239–255
5. Bannasch P, Reiss W (1971) Histogenese und Cyto-genese cholangiocellulärer Tumoren bei Nitrosomorpholin-vergifteten Ratten. *Zugleich ein Beitrag zur Morphogenese der Cystenleber.* *Z Krebsforsch* 76:193–215
6. Bannasch P, Moore MA, Klimek F, Zerban H (1982) Biological markers of preneoplastic foci and neoplastic nodules in rodent liver. *Toxicol Pathol* 10:19–34
7. Bannasch P, Hacker HJ, Klimek F, Mayer D (1984) Hepatocellular glycogenesis and related pattern of enzymatic changes during hepatocarcinogenesis. *Adv Enzyme Regul* 22:97–121
8. Criss WE (1969) A new pyruvate kinase isoenzyme in hepatomas. *Biochem Biophys Res Commun* 35:901–905
9. Eigenbrodt E, Fister P, Reinacher M (1985) New perspectives on carbohydrate metabolism. In: Beitner R (ed) *Regulation of carbohydrate metabolism.* CRC Press, Boca Raton, pp 141–179
10. Enzmann H, Bannasch P (1987) Potential significance of phenotypic heterogeneity of focal lesions at different stages in hepatocarcinogenesis. *Carcinogenesis* 8:1607–1612
11. Evarts RP, Nagy P, Thorgeirsson SS (1987) A precursor–product relationship exists between oval cells and hepatocytes in rat liver. *Carcinogenesis* 8:1737–1740
12. Evarts RP, Nagy P, Nakatsukasa H, Marsden E, Thorgeirsson SS (1987) In vivo differentiation of oval cells into hepatocytes. *Cancer Res* 49:1541–1547
13. Farina FA, Shatton JB, Morris HP, Weinhouse S (1974) Isoenzymes of pyruvate kinase in liver and hepatomas of the rat. *Cancer Res* 34:1439–1446
14. Fausto N (1990) Oval cells and liver carcinogenesis: an analysis of cell lineages in hepatic tumors using oncogene transfection techniques. *Prog Clin Biol Res* 331:325–334
15. Fischer G, Domingo M, Lodder, D, Katz N, Reinacher M, Eigenbrodt E (1987) Immunohistochemical demonstration of decreased L-pyruvate kinase in enzyme altered rat liver lesions produced by different carcinogens. *Virchows Arch [B]* 53: 359–364
16. Gerbracht U, Roth E, Becker K, Reinacher M, Eigenbrodt E (1988) A study of the activities of carbohydrate-metabolizing enzymes and the levels of carbohydrate metabolites and amino acids in normal liver and in hepatocellular carcinoma. In: Roberfroid MB, Pr at V (eds) *Experimental hepatocarcinogenesis.* Plenum Press, New York, pp 163–174
17. Gerbracht U, Wei e G, Schlatterer B, Reinacher M, Schulte-Hermann R, Eigenbrodt E (1988) Comparative study on the effect of different treatment schedules on some carbohydrate metabolizing enzyme activities in rats during hepatocarcinogenesis. In: Feo F, Pani P, Columbano A, Garcea R (eds) *Chemical carcinogenesis.* Plenum Press, New York, pp 323–335

18. Gerbracht U, Köpf G, Wüst G, Weiße G, Schlatterer B, Eigenbrodt E (1989) Study of nafenopin, a hypolipidemic drug, on liver metabolism. *Arch Toxicol [Suppl]* 13:304–308
19. Hacker HJ, Steinberg P, Toshkov I, Oesch F, Bannasch P (1992) Persistence of the cholangiocellular and hepatocellular lesions observed in rats fed a choline-deficient/DL-ethionine-supplemented diet. *Carcinogenesis* 13:271–276
20. Hacker HJ, Steinberg P, Bannasch P (1998) Pyruvate kinase isoenzyme shift from L- to M₂-type is a late event in hepatocarcinogenesis induced in rats by a choline-deficient/DL-ethionine-supplemented diet. *Carcinogenesis* 19:99–107
21. Klimek F, Bannasch P (1990) Biochemical microanalysis of pyruvate kinase activity in preneoplastic and neoplastic liver lesions induced in rats by *N*-nitrosomorpholine. *Carcinogenesis* 11:1377–1380
22. Klimek F, Moore MA, Schneider E, Bannasch P (1988) Histochemical and microbiological demonstration of reduced pyruvate kinase activity in thioacetamide-induced neoplastic nodules of rat liver. *Histochemistry* 90:37–42
23. Lemire JM, Shiojiri N, Fausto N (1991) Oval cell proliferation and the origin of small hepatocytes in liver injury induced by D-galactosamine. *Am J Pathol* 139:535–552
24. Ponder KP (1996) Analysis of liver development, regeneration, and carcinogenesis by genetic marking studies. *FASEB J* 10:673–684
25. Reinacher M, Eigenbrodt E, Gerbracht U, Zenk G, Timmermann-Trosiener I, Bentley P, Waechter F, Schulte-Hermann R (1986) Pyruvate kinase isoenzymes in altered foci and carcinoma of rat liver. *Carcinogenesis* 7:1351–1357
26. Sato K, Takaya S, Imai F, Hatayama I, Ito N (1978) Different deviation patterns of carbohydrate metabolizing enzymes in primary rat hepatomas induced by different chemical carcinogens. *Cancer Res* 38:3086–3093
27. Sell S (1990) Is there a liver stem cell? *Cancer Res* 50:3811–3815
28. Sigal SH, Brill S, Fiorino AS, Reid LM (1992) The liver as a stem cell and lineage system. *Am J Physiol* 263:G139–G148
29. Silber D, Checinska E, Rabczynski J, Kasprzak AA, Kochmann M (1978) Isoenzyme pattern of pyruvate kinase during hepatocarcinogenesis induced by 2-acetylaminofluorene in rat liver. *Eur J Cancer* 14:729–739
30. Steinberg P, Hacker HJ, Dienes HP, Oesch F, Bannasch P (1991) Enzyme histochemical and immunohistochemical characterization of oval and parenchymal cells proliferating in livers of rats fed a choline-deficient/DL-ethionine-supplemented diet. *Carcinogenesis* 12:225–231
31. Steinberg P, Weiße G, Eigenbrodt E, Oesch F (1994) Expression of L- and M₂-pyruvate kinases in proliferating oval cells and cholangiocellular lesions developing in the livers of rats fed a methyl-deficient diet. *Carcinogenesis* 15:125–127
32. Taylor CB, Morris HP, Weber G (1969) A comparison of the properties of pyruvate kinase from hepatoma 3924A, normal liver and muscle. *Life Sci* 8:635–644
33. Tee LBG, Smith PGJ, Yeoh GCT (1992) Expression of alpha, mu and pi class glutathione *S*-transferases in oval and ductal cells in liver of rats placed on a choline-deficient, ethionine-supplemented diet. *Carcinogenesis* 13:1879–1885
34. Tee LBG, Kirilak Y, Huang W-H, Morgan RH, Yeoh GCT (1994) Differentiation of oval cells into duct-like cells in preneoplastic liver of rats placed on a choline-deficient diet supplemented with ethionine. *Carcinogenesis* 15:2747–2756
35. Tee LBG, Kirilak Y, Huang W-H, Smith PGJ, Morgan RH, Yeoh GCT (1996) Dual phenotypic expression of hepatocyte and bile ductular markers in developing and preneoplastic rat liver. *Carcinogenesis* 17:251–259
36. Tian Y-W, Smith PGJ, Yeoh GCT (1997) The oval-shaped cell as a candidate for a liver stem cell in embryonic, neonatal and precancerous liver: identification based on morphology and immunohistochemical staining for albumin and pyruvate kinase isoenzyme expression. *Histochem Cell Biol* 107:243–250
37. Walker PR, Potter VR (1972) Isozyme studies on adult, regenerating, precancerous and developing liver in relation to findings in hepatomas. *Adv Enzyme Regul* 10:339–364
38. Weber G, Morris HP (1963) Comparative biochemistry of hepatomas. III. Carbohydrate enzymes in liver tumors of different growth rates. *Cancer Res* 23:987–994
39. Yanagi S, Makiura S, Aroi M, Matsumara K, Hirao K, Ito N, Tanaka T (1974) Isoenzyme patterns of pyruvate kinase in various primary liver tumors induced during the process of hepatocarcinogenesis. *Cancer Res* 34:2283–2289